Image-Guided High-Dose Rate Intracavitary Brachytherapy in the Treatment of Medically Inoperable Early-Stage Endometrioid Type Endometrial Adenocarcinoma

Scott E. Jordan, MD
Temple Health Fox Chase Cancer Center

Ida Micaily, MD
Abington Jefferson Health

Enrique Hernandez, MD
Temple University

Curtis T. Miyamoto, MD, FACR
Temple University

Recommended Citation
Jordan, MD, Scott E.; Micaily, MD, Ida; Hernandez, MD, Enrique; Ferriss, MD, J. Stuart; Miyamoto, MD, FACR, Curtis T.; Li, PhD, Shidong; and Micaily, MD, Bizhan, "Image-Guided High-Dose Rate Intracavitary Brachytherapy in the Treatment of Medically Inoperable Early-Stage Endometrioid Type Endometrial Adenocarcinoma" (2017). Division of Internal Medicine Faculty Papers & Presentations. Paper 19.
https://jdc.jefferson.edu/internalfp/19
Authors
Scott E. Jordan, MD; Ida Micaily, MD; Enrique Hernandez, MD; J. Stuart Ferriss, MD; Curtis T. Miyamoto, MD, FACP; Shidong Li, PhD; and Bizhan Micaily, MD

This poster is available at Jefferson Digital Commons: https://jdc.jefferson.edu/internalfp/19
In patients with multiple medical comorbidities which preclude surgical therapy for early stage endometrioid type endometrial cancer, with medical conditions precluding surgical management treated at Temple University Hospital since 2010 were reviewed. Exclusion criteria included any evidence of nodal or cervical disease, or histologic types other than endometrioid.

All treatment planning utilized CT imaging following placement of HDR applicators ( tandem with ring or tandem with yokes). Prior to 2016, a high-risk clinical target volume was defined by the radiation oncologist as approximately 25% in myometrial depth. In 2016, a protocol was initiated where gross tumor volume (GTV) was defined as the entire uterine cavity, cervix, and proximal 4 cm of the vagina.

METHODS

RESULTS

CONCLUSIONS

Acknowledgements

References

Contact Information